Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

SEC Filings

10-K
PACIRA PHARMACEUTICALS, INC. filed this Form 10-K on 03/01/2017
Entire Document
 << Previous Page | Next Page >>

PACIRA PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
 
December 31,
 
2016
 
2015
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
35,944

 
$
56,984

Short-term investments
136,653

 
101,981

Accounts receivable, net
29,937

 
25,855

Inventories, net
31,278

 
61,645

Prepaid expenses and other current assets
9,277

 
6,117

Total current assets
243,089

 
252,582

Long-term investments

 
13,462

Fixed assets, net
101,016

 
90,324

Goodwill
46,737

 
30,880

Intangibles, net

 
81

Other assets
624

 
406

Total assets
$
391,466

 
$
387,735

 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
7,511

 
$
8,739

Accrued expenses
36,666

 
35,375

Convertible senior notes

 
104,040

Current portion of deferred revenue
595

 
1,426

Income taxes payable
66

 
208

Total current liabilities
44,838

 
149,788

Convertible senior notes
108,738

 

Deferred revenue
7,487

 
8,082

Other liabilities
11,427

 
11,473

Total liabilities
172,490

 
169,343

Commitments and contingencies (Note 17)

 

Stockholders’ equity:
 
 
 
Preferred stock, par value $0.001; 5,000,000 shares authorized, none issued and outstanding at December 31, 2016 and 2015

 

Common stock, par value $0.001 and 250,000,000 shares authorized; 37,480,952 shares issued and outstanding at December 31, 2016; 36,848,319 shares issued and outstanding at December 31, 2015
37

 
37

Additional paid-in capital
565,207

 
526,696

Accumulated deficit
(346,238
)
 
(308,289
)
Accumulated other comprehensive loss
(30
)
 
(52
)
Total stockholders’ equity
218,976

 
218,392

Total liabilities and stockholders’ equity
$
391,466

 
$
387,735

See accompanying notes to consolidated financial statements.

F-4

 << Previous Page | Next Page >>

Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com


IHI/NPSF Project Seeks to Improve the Assessment and Management of Acute Pain
Click here for more...